Newton Bishop JA, Harland M, Bennett DC, Bataille V, Goldstein AM, Tucker MA, Ponder BAJ, Cuzick J, Selby P, Bishop DT.
Mutation testing in melanoma families: INK4A, CDK4, and INK4D.
Br J Cancer 1999;80:295-300.

Shennan MG, Badin AC, Walsh S, Summers A, From L, McKenzie M, Goldstein AM, Tucker MA, Hogg D, Lassam N.
Lack of germline CDK6 mutations in familial melanoma.
Oncogene 2000;19:1849-1852.

Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA.
Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
J Natl Cancer Inst 2000;92:1006-1010.

Harland M, Holland EA, Ghiorzo P, Mantelli M, Bianchi-Scarra G, Goldstein AM, Tucker MA, Ponder BAJ, Mann GJ, Bishop DT, Newton Bishop J.
Mutation screening of the CDKN2A promoter in melanoma families.
Genes Chromosomes Cancer 2000;28:45-57.

Ciotti P, Struewing JP, Mantelli M, Chompret A, Avril MF, Santi PL, Tucker MA, Bianchi-Scarra G*, Bressac-de Paillerets B*, Goldstein AM*.
A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families.
Am J Hum Genet 2000;67:311-319.

Goldstein AM, Martinez M, Tucker MA, Demenais F.
Gene-covariate interaction between dysplastic nevi and the CDKN2A gene in American melanoma-prone families.
Cancer Epidemiol Biomarkers Prev 2000;9:889-894.

Auroy S, Avril MF, Chompret A, Pham D, Goldstein AM, Bianchi-Scarra G, Frebourg T, Joly P, Spatz SA, Rubino C, Demenais F, French
Hereditary Melanoma Study Group, Bressac-de Paillerets B. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect.
Genes Chromosomes Cancer 2001;32:195-202.

Goldstein AM, Liu L, Shennan MG, Hogg D, Tucker MA, Struewing JP.
A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families.
Br J Cancer 2001;85:527-530.

Goldstein AM, Tucker MA.
Genetic epidemiology of cutaneous melanoma – A global perspective.
Arch Dermatol 2001;137:1493-1496.

Mantelli M, Barile M, Ciotti P, Ghiorzo P, Lantieri F, Pastorino L, Catricalà C, Torre GD, Folco U, Grammatico P, Padovani L, Pasini B, Rovini D, Queirolo P, Rainero ML, Santi PL, Sertoli RM, Goldstein AM, Società Italiana Dermatologia e Venerologia Gruppo Italiano Studi Epidemiologici in Dermatologia, Bianchi-Scarrà G.
High prevalence of the G101W germline mutation in the CDKN2A (P16ink4a) gene in 62 Italian malignant melanoma families.
Am J Med Genet 2002;107:214-221.

Tucker MA, Fraser MC, Goldstein AM, Struewing JP, King MA, Crawford JT, Chiazze EA, Zametkin DP, Fontaine LS, Clark WH, Jr.
A natural history of melanomas and dysplastic nevi: An atlas of lesions in melanoma-prone families.
Cancer 2002;94:3192-3209.

Bishop DT*, Demenais F*, Goldstein AM*, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J, Harland M, Hayward N, Holland EA, Mann GJ, Mantelli M, Nancarrow D, Platz A, Tucker MA, The Melanoma Genetics Consortium.
Geographical variation in the penetrance of CDKN2A mutations for melanoma.
J Natl Cancer Inst 2002;94:894-903.

Feng Y, Shi J, Goldstein AM, Tucker MA, Nelson MA.
Analysis of mutations and identification of several polymorphisms in the putative promoter region of the p34CDC2-related CDC2L1 gene located at 1p36 in melanoma cell lines and melanoma families.
Int J Cancer 2002;99:834-838.

Kefford R, Newton Bishop J, Tucker M, Bressac-de Paillerets B, Bianchi-Scarra G, Bergman W, Goldstein A, Puig S, Mackie R, Elder D, Hansson J, Hayward N, Hogg D, Olsson H, on behalf of the Melanoma Genetics Consortium.
Genetic testing for melanoma.
Lancet Oncol 2002; 3:653-4.

Tucker MA, Goldstein AM.
Melanoma etiology: where are we?
Oncogene 2003;22:3042-3052.

Tucker MA, Fraser MC, Goldstein AM, Struewing JP, King MA, Crawford JT, Chiazze EA, Zametkin DP, Fontaine LS, Clark WH, Jr.
A natural history of melanomas and dysplastic nevi: An atlas of lesions in melanoma-prone families.
Dermatol Nursing 2003;15:237-253.